Abstract
Objective To determine the SARS-CoV-2 seroprevalence among school workers in the setting of full in-person schooling and the highly transmissible Omicron variants of concern.
Design Cross-sectional study among school staff, comparing to period-, age-, sex- and postal code-weighted data from Canadian blood donors from the same community.
Setting Three large school districts in the greater Vancouver metropolitan area, British Columbia, Canada, with serology sampling done between January 26, 2022 and April 8, 2022.
Participants School staff actively working in the Vancouver, Richmond and Delta School Districts.
Main outcome measure SARS-CoV-2 seroprevalence based on nucleocapsid (N)-protein testing, adjusted for the sensitivity and specificity of the assay.
Results A majority (65.8%) of the 1845 school staff enrolled reported close contact with a COVID-19 case outside the household. Of those, about half reported close contact with a COVID-19 case at school either in a student (51.5%) or co-worker (54.9%). In a representative sample of 1620 (87.8%) school staff, the adjusted seroprevalence was 26.5% [95%CrI: 23.9 – 29.3%]. This compared to an age, sex and residency area-weighted seroprevalence of 32.4% [95%CrI: 30.6 – 34.5%] among 7164 blood donors.
Conclusion Despite frequent COVID-19 exposures, the prevalence of SARS-CoV-2 infections among the staff of three main school districts in the Vancouver metropolitan area was no greater than a reference group of blood donors, even after the emergence of the more transmissible Omicron variant.
What is already known on this subject?
Earlier studies indicate that COVID-19 infection rates are not increased among school staff at previous stages of the pandemic compared to the community, yet controversy remains whether this will remain true after the emergence of the highly transmissible Omicron variant.
What this study adds?
Despite frequent COVID-19 exposures, this study identified no detectable increase in SARS-CoV-2 seroprevalence among school staff working in three metro Vancouver public school districts after the first Omicron wave in British Columbia, compared to a reference group of blood donors from the same age, sex and community area.
Competing Interest Statement
CO is an employee of the Vancouver School District, but the latter was not involved in the design, analysis, interpretation of the data, or the drafting of this manuscript. LifeLabs played no role in the study other than providing a service for the collection of blood samples. The study was funded by the Government of Canada via its COVID-19 Immunity Task Force (to PML and LCM as co-principal applicant; award # AWD 016994). PML and LCM receive a salary from the British Columbia Childrens Hospital (BCCH) Foundation through the Investigator Grant Award Program (award number is not applicable). The BC Childrens Hospital Healthy Starts Theme provided some seed funding at the beginning of the study (award number is not applicable). Authors declare no relevant conflicts of interest.
Funding Statement
The study was funded by the Government of Canada via its COVID-19 Immunity Task Force (to PML and LCM as co-principal applicant; award # AWD 016994). PML and LCM receive a salary from the British Columbia Childrens Hospital (BCCH) Foundation through the Investigator Grant Award Program (award number is not applicable). The BC Childrens Hospital Healthy Starts Theme provided some seed funding at the beginning of the study (award number is not applicable).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of British Columbia Children's and Women's Research Ethics Board gave ethical approval of this work (H20 03593).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data will be made available through the COVID-19 Immunity Task Force.